(TheNewswire)
MISSISSAUGA, Ontario – TheNewswire - April 19, 2021 – Sire Bioscience Inc.(CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (CNSX:SIRE.CN) (“ SIRE ” or the “ Company ”) is pleased to announce that, inaddition to Purple K, Canada’s top selling creatine pills, theCompany’s wholly owned subsidiary, Fusion Nutrition Inc.(“ Fusion ”) in the coming 12 weeks will be launching 3 new creatineproducts:
-
- Purple K powder
- Purple K PURE capsule
- Purple K PURE powder
Brian Polla, CEO, COO and a director of the Companycommented: “ For the first time under newmanagement Fusion is shipping and selling products directly from theUnited States. This presents us with a significant potential newclient base. This is the first country that we have opened, outside ofCanada. Based on the market research we have conducted; we expectstrong success with the launch of these new products”.
The Canadian Securities Exchange(“CSE”) has neither approved nor disapproved the contents of thisnews release. Neither the CSE nor its Market Regulator (as that termis defined in the policies of the CSE) accepts responsibility for theadequacy or accuracy of this release.
About Sire Bioscience
SIRE is headquartered in Mississauga, Ontario, and ismanaged by a group of successful entrepreneurs who have extensiveexperience in the areas of consumer-packaged goods, manufacturing,logistics, and distribution. SIRE is a CPG life science companyfocused on the plant-based foods and supplements industry.
For additional informationcontact:
Sire Bioscience Inc.
Website: sirebioscience.com
Socials: @sirebioscience
Forward?Looking InformationCautionary Statement
This press release may contain certain“forward-looking information” and “forward-looking statements”within the meaning of applicable Canadian securities legislation. Allinformation contained herein that is not historical in nature mayconstitute forward-looking information. Forward-looking statements maybe identified by statements containing the words “believes”,“anticipates”, “plans”, “intends”, “will”,“should”, “expects”, “continue”, “estimate”,“forecasts” and other similar expressions. Forward-lookingstatements herein include, but are not limited to, statementsexpectations of management’s focus on and growth expectations of theFusion product lines and the Company’s business and strategic plans.Readers are cautioned to not place undue reliance on forward-lookinginformation. Actual results and developments may differ materiallyfrom those contemplated by these statements. SIRE undertakes noobligation to comment on analyses, expectations or statements made bythird parties in respect of SIRE, its securities, or financial oroperating results (as applicable). Although SIRE believes that theexpectations reflected in forward-looking statements in this pressrelease are reasonable, such forward-looking statement has been basedon expectations, factors and assumptions concerning future eventswhich may prove to be inaccurate and are subject to numerous risks anduncertainties, certain of which are beyond SIRE’s control, includingthe risk factors discussed in SIRE’s Listing Statement dated August22, 2019 which is available on SIRE’s SEDAR profile at www.sedar.com . Theforward-looking information contained in this press release isexpressly qualified by this cautionary statement and are made as ofthe date hereof. SIRE disclaims any intention and has no obligation orresponsibility, except as required by law, to update or revise anyforward-looking information, whether as a result of new information,future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.